ライフサイエンスコーパス: ovalbumin

1 (human transferrin, human serum albumin, and ovalbumin).

2 d desensitization to the model food allergen ovalbumin.

3 rcutaneous challenge by the protein allergen ovalbumin.

4 airway epithelium were tolerized to inhaled ovalbumin.

5 deled in mice sensitized and challenged with ovalbumin.

6 ngth) produced a Th2-biased response against ovalbumin.

7 H2 responses after allergic sensitization to ovalbumin.

8 nternalized by dendritic cells and delivered ovalbumin.

9 ntraperitoneally toward the primary antigen, ovalbumin.

10 ild-type (WT) mice sensitized and exposed to ovalbumin.

11 ration of antibodies after immunization with ovalbumin.

12 roteases which were not accessible in native ovalbumin.

13 n was prepared by conjugating [Asp3]MC-RY to ovalbumin.

14 e of Galbeta(1-->4)GlcNAc ligands on chicken ovalbumin.

15 pidly after sensitization and challenge with ovalbumin.

16 ollowed by injection of 2,4,6-trinitrophenyl-ovalbumin.

17 from mice sensitized to native or aggregated ovalbumin.

18 Rats were sensitized with ovalbumin (1 mg SC), and anaphylactic shock was induced

19 ylactic shock was induced by IV injection of ovalbumin (1 mg).

20 cytosolic antigen levels relative to soluble ovalbumin 4h post uptake.

21 Ovalbumin, a major allergen in egg whites, is prone to a

22 Preimmunization with CM but not control ovalbumin abrogated the graft prolonging effects of DST/

23 3beta) sequences following immunization with ovalbumin administered with complete Freund's adjuvant (

24 eally injected into ovalbumin-sensitized and ovalbumin aerosol-challenged leukotriene C4 synthase-def

25 accurately identify a CD4 T cell response to ovalbumin against a background response to the complex m

26 entification using LC-MS/MS highlighted that ovalbumin aggregation rendered a number of peptide bonds

27 als were exposed repeatedly to aspiration of ovalbumin alone or together with environmental adjuvants

28 -alum, followed by intranasal challenge with ovalbumin alone, to induce adaptive TH2 responses.

29 model of allergic asthma was developed with ovalbumin-alum in female Cd39 wild type (Cd39(+/+) ) and

30 Mice were sensitized with intraperitoneal ovalbumin-alum, followed by intranasal challenge with ov

31 tolerance in a murine model of Th2-mediated ovalbumin/alum-induced allergic airway inflammation.

32 cross-presentation in vitro relative to free ovalbumin, an unconjugated physical mixture of ovalbumin

33 -) mice and subsequently exposed the mice to ovalbumin and a cysteine protease.

34 erformed intranasally or epicutaneously with ovalbumin and a secondary antigen, keyhole limpet hemocy

35 e adaptive allergic inflammatory response to ovalbumin and alum was unimpaired.

36 nd exposed to two separate allergic stimuli (ovalbumin and Aspergillus extract), genetic removal of M

37 Using ovalbumin and Bacillus anthracis protective antigen prot

38 DA neurons internalize foreign ovalbumin and display antigen derived from this protein

39 of glycopeptides from fetuin, glycophorin A, ovalbumin and gp120 tryptic digests were used to build a

40 inhibitor-treated animals were challenged in ovalbumin and house dust mite models of AAI.

41 ferent murine models of experimental asthma (ovalbumin and house dust mite); miRNAs deregulated in bo

42 Ovalbumin and immunoglobulin Y are selected as analytes

43 Susceptibility to pepsinolysis of ovalbumin and lysozyme was markedly enhanced by heating

44 LDI-MS identified proteolytic fragments from ovalbumin and lysozyme, exhibiting varied resistance to

45 Compared to ovalbumin and lysozyme, ovotransferrin was more suscepti

46 zyme were influenced by the treatment, while ovalbumin and ovomucoid were not affected.

47 variable regions) upon the immunization with ovalbumin and papain.

48 tion against the anaphylaxis associated with ovalbumin and peanut allergy and affects the epigenome o

49 This Vaccine-NP was compared to ovalbumin and poly(I:C) formulated in a similar manner (

50 mpared to immunization with soluble protein, ovalbumin and polymer mixture, and the control micelle w

51 albumin, an unconjugated physical mixture of ovalbumin and polymer, and a non-pH-responsive micelle-o

52 The effect of the presence of ovalbumin and soy protein isolate on lipolysis and oxida

53 BALB/c mice were sensitized to ovalbumin and subsequent airway ovalbumin challenge.

54 is, estimated by the disappearance of intact ovalbumin and the appearance of soluble peptides, was gr

55 oups for reversible conjugation of thiolated ovalbumin, and a tercopolymer ampholytic core-forming bl

56 f polymer type (proteins, i.e. caseinate and ovalbumin, and polysaccharides, i.e. alginate and methyl

57 ngly, serpins are homologs of the well-known ovalbumin antigen and are associated with autoimmunity.

58 d standards from an Abl kinase sensor and an ovalbumin antigenic peptide were then employed to identi

59 In the present study, using ovalbumin as a model antigen adsorbed onto aluminum hydr

60 s shown by both the astringency method (with ovalbumin as a precipitant) and the tannins determinatio

61 f these mice with house dust mite extract or ovalbumin as allergens led to exacerbated inflammation,

62 We showed that heat aggregation of ovalbumin as large particles enhances IgG production and

63 xpress luciferase (for in vivo tracking) and ovalbumin (as a model antigen).

64 yptophan depletion in myofibrillar proteins, ovalbumin, beta-lactoglobulin, soy protein and human ser

65 revealed that calcium inhibited glycation of ovalbumin by a mixed non-competitive mechanism in both d

66 A knockout mice (P < .005) and in vivo after ovalbumin challenge (P < .05), higher levels of apoptosi

67 Following ovalbumin challenge on days 40-42, CAIKKbeta mice in whi

68 Sensitised mice were exposed to prolonged ovalbumin challenge or continuous house-dust mite exposu

69 ensitized to ovalbumin and subsequent airway ovalbumin challenge.

70 ypertrophy in the lungs of a murine model of ovalbumin-challenged allergic asthma, leading to improve

71 mulin plasmids were detected in the lungs of ovalbumin-challenged asthmatic mice up to 27days after a

72 TLR7 signaling was also evaluated in ovalbumin-challenged guinea pigs.

73 ectrodeposition and used to conjugate the HA ovalbumin conjugate (HA-Ag).

74 Approximately 90% of initially internalized ovalbumin-conjugated micelles were retained in cells aft

75 le types was optimized to achieve ~50 mug of ovalbumin conjugation per mg of particle.

76 Ovalbumin conjugation to these different particle types

77 umin ratio, yolk index, air cell size, and S-ovalbumin content of UC were significantly the most supe

78 and polymer, and a non-pH-responsive micelle-ovalbumin control.

79 ed control rats received only vehicle and no ovalbumin (control group).

80 systemically applied (64)Cu-labeled chicken ovalbumin (cOVA)-TCR transgenic T cells into the pulmona

81 s on proteins (as caseins, whey proteins and ovalbumin) declared in the label of several sport nutrit

82 We induced ovalbumin-dependent colitis in mice that express ovalbum

83 Two novel ovalbumin-derived tetrapeptides: SWVE (f 148-151) and DI

84 of heat-induced aggregation on the extent of ovalbumin digestion and the nature of peptides released

85 Aggregated ovalbumin displayed lower Ig-binding and basophil-activa

86 otein effects with bovine serum albumin, (S-)ovalbumin, egg white, whole egg, defatted egg yolk, whea

87 sters, which were mainly composed of chicken ovalbumin-encapsulated AuNCs, can recognize ricin B beca

88 In contrast, an ovalbumin epitope peptide was degraded at 8.9 +/- 0.1 zm

89 driven by adoptively transferred, traceable ovalbumin-experienced Th2 cells.

90 cific T cells specific for the model antigen ovalbumin expressed by engineered parasites.

91 an in vivo mouse model of nasal tolerance to ovalbumin, F. prausnitzii A2-165 enhanced ovalbumin-spec

92 ansgenic CD4(+) T-cell receptor specific for ovalbumin failed to develop HF and adverse remodeling.

93 Ovalbumin family contains three proteins with high seque

94 Immunization of F344 rats against ovalbumin followed by intranasal challenges with ovalbum

95 Intrarectal application of ovalbumin followed by transfer of CD8 OT-I T cells led t

96 suggest that the final coating of dissolved ovalbumin from egg white after long exposure to air, whi

97 Model systems composed of ovalbumin, glucose, and anti-glycation agents (tannic ac

98 n of non-entrapped drug present) or protein (ovalbumin >90% reduction of OVA present) and organic sol

99 tactin, Cytochrome C, holo hemoglobin-alpha, ovalbumin, human transthyretin, avidin, bovine serum alb

100 sing the HOD antigen (hen egg lysozyme [HEL]-ovalbumin-human transmembrane Duffy(b)) were transfused

101 d that the AuNCs@ew were mainly derived from ovalbumin, i.e., the major protein in egg white, encapsu

102 Cs purified from the draining lymph nodes of ovalbumin-immunized mice favored the generation of antig

103 the TH2-inducing antigens house dust mite or ovalbumin in a model of allergic airway inflammation or

104 after challenge of Spi2A knockout mice with ovalbumin in alum.

105 bumin-dependent colitis in mice that express ovalbumin in biliary epithelia (ASBT-OVA mice) and cross

106 crossed ASBT-OVA mice with mice that express ovalbumin in enterocytes (iFABP-OVA mice).

107 when it is aggregated as large particles to ovalbumin in its native form.

108 The immune response to intranasal ovalbumin in mice was assessed with concomitant infectio

109 valuating model antigens such as chicken egg ovalbumin in mouse models but their relevance to humans

110 ompared to the native secondary structure of ovalbumin in solution of circa 33% alpha-helix and beta-

111 responses against the encapsulated antigen (ovalbumin) in mice.

112 bumin followed by intranasal challenges with ovalbumin induced airway hyper-reactivity, which was red

113 The pathology of ovalbumin-induced acute allergic airway inflammation aft

114 The development of ovalbumin-induced AD-like skin lesions was analysed in H

115 Ovalbumin-induced allergic airway inflammation was analy

116 n-1) PSCs was studied in an in vivo model of ovalbumin-induced allergic inflammation and an in vitro

117 Similarly, during ovalbumin-induced allergic inflammation, pulmonary recru

118 Using the ovalbumin-induced allergic lung inflammation model, we f

119 nerated using passive cutaneous anaphylaxis, ovalbumin-induced asthma and arthritis models.

120 isothiocyanate contact hypersensitivity and ovalbumin-induced dermatitis as models for TH2-mediated

121 uced muscular inflammations, and (c) bearing ovalbumin-induced lung inflammations.

122 pleted of Ly49A/D/G(+) NK cell subsets in an ovalbumin-induced model of allergic airway disease (OVA-

123 Rats with the ovalbumin-induced model of asthma had elevated levels of

124 Haemophilus respiratory infection-mediated, ovalbumin-induced severe, steroid-resistant allergic air

125 ytial virus respiratory tract infections and ovalbumin-induced, severe, steroid-insensitive allergic

126 Ovalbumin is the major egg white protein with still unde

127 In this study, chicken egg white ovalbumin is used as a model for the study of fibril loo

128 knockout mice with EpCAM-deficient LCs with ovalbumin led to increased induction of type 2 Ova-speci

129 an aqueous two-phase system (ATPS) using an ovalbumin-methylcellulose system (OMCS) in comparison to

130 of activation of CD8+ T cells in an in vitro ovalbumin model and illustrated that acid-labile polymer

131 Using the ovalbumin model antigen system, anti-CD47 antibody-media

132 orted that K14-mOVA mice expressing membrane ovalbumin (mOVA), driven by the keratin 14 (K14) promote

133 immune-modulating properties of MVA-encoding ovalbumin (MVA-OVA) on the allergen-specific immune resp

134 Modified vaccinia virus Ankara-ovalbumin (MVA-OVA) vaccination induces a strong OVA-spe

135 The setup is tested with the protein ovalbumin (MW approximately 44.3 kDa) and its clusters u

136 control vs sensitized and/or challenged with ovalbumin, n=3-5/group) 6 hour, 24 hour, and 48 hour aft

137 etween heat-induced aggregates of ovalbumin (ovalbumin nanoparticles, OVAn) and linoleic acid (LA) we

138 Ovalbumin-obese mice treated with NK1-R antagonist had l

139 wed by five oral dosing with purified AHC or ovalbumin on alternate days and continued on HFD for ano

140 pendence of the apparent molecular weight of ovalbumin on buffer concentration are extrapolated to ze

141 o dog-associated house dust protects against ovalbumin or cockroach allergen-mediated airway patholog

142 this murine model was exposed to allergens (ovalbumin or house dust mite extract) to decipher in viv

143 RAs) and assessed their abilities to reverse ovalbumin or peanut allergies in mouse models, as well a

144 C-RAs to half-maximally sensitized mice with ovalbumin or peanut allergy reduced anaphylactic respons

145 ols for food allergy induction, using either ovalbumin or peanut extract as allergens for sensitizati

146 fluenza and, once recovered, subjected to an ovalbumin- or house dust mite-induced experimental asthm

147 lly block nociceptors, substantially reduced ovalbumin- or house-dust-mite-induced airway inflammatio

148 I cells and cognate peptide stimulation with ovalbumin (OVA) 323-339 plus the inflammatory adjuvant,

149 ittermates were sensitized and challenged to ovalbumin (OVA) 7 or 11 times.

150 exacerbated juvenile airway disease using an ovalbumin (OVA) allergy model of asthma.

151 Furthermore, NPs co-loaded with ovalbumin (OVA) and a molecular adjuvant, monophosphoryl

152 Female Balb/c mice were sensitized to ovalbumin (OVA) and challenged with an OVA-aerosol on tw

153 SIGIRR(-/-) C57BL/6 mice were sensitized to ovalbumin (OVA) and challenged with OVA aerosol to induc

154 -deficient (miR-155(-/-) ) mice were used in ovalbumin (OVA) and house dust mite (HDM) models of AAI.

155 xpression and activity were evaluated in the ovalbumin (OVA) and house dust mite (HDM) murine models.

156 We employed acute ovalbumin (OVA) and house dust mite (HDM) sensitization

157 dine or activated using dimaprit in both the ovalbumin (OVA) and house dust mite extract (HDM) murine

158 mmation was induced through sensitization to ovalbumin (OVA) and repeated airway OVA challenge.

159 sh) mice were epicutaneously sensitized with ovalbumin (OVA) and then challenged orally with OVA.

160 tudy of labeling of thiolic groups of native ovalbumin (OVA) as a function of protein concentration.

161 We developed CH-NPs encapsulating ovalbumin (OVA) as a model antigen and poly I:C as the a

162 Using ovalbumin (OVA) as a model antigen, LSs formulated with

163 evidence in a transgenic mouse system using ovalbumin (OVA) as a model surrogate TRA that the de nov

164 We showed that an ovalbumin (OVA) asthma protocol presented a significant

165 ose on anaphylactic symptoms induced by oral ovalbumin (OVA) challenge in sensitized mice were invest

166 lavage (BAL) simultaneously, 6 h after each ovalbumin (OVA) challenge.

167 rghei parasites expressing the model antigen ovalbumin (OVA) either in the parasite cytoplasm or on t

168 e epicutaneously sensitized female mice with ovalbumin (OVA) followed by epicutaneous sensitization a

169 B/c mice were sensitized and challenged with ovalbumin (OVA) followed with fasudil treatment.

170 re intratracheally challenged with PM2.5 +/- ovalbumin (OVA) four times at 2-week intervals.

171 6 mice by intraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exp

172 tes uptake and processing of soluble antigen ovalbumin (Ova) in primary human macrophages and dendrit

173 Oral administration of ovalbumin (OVA) in Was(-/-) mice induced low titers of O

174 In addition, immunization with ovalbumin (OVA) induced OVA-specific B cells only in hum

175 model in which instillation of ClO(-) before ovalbumin (OVA) induces AHR without bronchial inflammato

176 80% sulforhodamine b (SRB) and model antigen ovalbumin (OVA) into murine, swine, and human skin withi

177 type (WT) and B cell-deficient mice received ovalbumin (OVA) intranasally before mating.

178 C57BL/6 mice were either sensitized to ovalbumin (OVA) intraperitoneally or through adoptive tr

179 fractionally coated with a powder mixture of ovalbumin (OVA) model allergen, CpG, and 1,25-dihydroxyv

180 c T cell receptor (TCR) with specificity for ovalbumin (OVA) on CD4(+)-T cells and cMy-mOVA mice expr

181 While allergenic challenge with a low-dose ovalbumin (OVA) only produced a small bronchospasm (~2-f

182 Mice were sensitized and challenged with ovalbumin (OVA) or cockroach extract (CE).

183 ary during the sensitization phase of either ovalbumin (OVA) or house dust mite (HDM) acute asthma mo

184 to wild-type recipient mice, challenged with ovalbumin (OVA) or house dust mite (HDM), and accessed f

185 ay inflammation in mice administering either ovalbumin (OVA) or house dust mite extract (HDM) for sen

186 t suboptimal immunization and challenge with ovalbumin (OVA) or received PBS.

187 spheres bound and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1.

188 C3H/HeJ mice were sensitized to ovalbumin (OVA) orally or through the skin and treated w

189 e that received an irrelevant immunodominant ovalbumin (OVA) peptide, OVA323-339, mice that received

190 rformed by applying a skin patch soaked with ovalbumin (OVA) plus CpG, and its suppressor activity wa

191 ARRY-063 was administered orally to ovalbumin (OVA) sensitized and challenged mice.

192 EW SPT and ovalbumin (OVA) sIgE have the best area under the curve

193 Thus, we labeled ovalbumin (OVA) T-cell receptor transgenic interferon (I

194 e and IP knockout mice were aerosolized with ovalbumin (OVA) to induce immune tolerance prior to immu

195 In utero injection of adjuvant-free ovalbumin (OVA) was conducted in Gestational Day 14 FVB/

196 Ovalbumin (OVA) was instilled into the airways of mice t

197 y, amyloids assembled from the model protein ovalbumin (OVA) were found to release the precursor prot

198 We show that the modification of Ovalbumin (OVA) with the glycan-structure Lewis(X) (Le(X

199 Animals were exposed to intranasal ovalbumin (OVA) without systemic sensitization.

200 their physical properties then conjugated to ovalbumin (OVA), a model antigen.

201 N microparticles co-loaded with the antigen, ovalbumin (OVA), and adjuvant, CpG 1826, (PNSN(OVA + CpG

202 /-) mice were sensitized and challenged with ovalbumin (OVA), and the development of AAD was ascertai

203 In addition to the main egg allergens: ovalbumin (OVA), ovomucoid (OM) and lysozyme (LYS), two

204 s an IgG1 B cell receptor (BCR) specific for ovalbumin (OVA), the epitope of which can be mimicked us

205 ) was used to produce exosomes together with ovalbumin (OVA), the resulting Dexo vaccine strongly sti

206 the dose and penetration of a model vaccine, Ovalbumin (OVA), to depths of 500mum into porcine skin.

207 Cell culture and ovalbumin (OVA)- or house dust mite-based murine asthma

208 Egg white (EW)-, ovalbumin (OVA)-, and ovomucoid (OVM)-specific levels of

209 XCL1 (KC) expression were also determined in ovalbumin (OVA)-challenged wild-type female recipient mi

210 Pulmonary immunization with ovalbumin (OVA)-conjugated cationic NPs led to enhanced

211 to T and B cell responses of unimmunized and ovalbumin (OVA)-immunized BALB/c mice, and furthermore,

212 taneous preventive allergy treatment against ovalbumin (Ova)-induced airway allergy in mice.

213 of TH subsets in vitro and on development of ovalbumin (OVA)-induced airway hyperresponsiveness (AHR)

214 s was assessed in whole lungs from mice with ovalbumin (OVA)-induced allergic airway inflammation (AA

215 his study, we used a neonatal mouse model of ovalbumin (OVA)-induced allergic airway inflammation to

216 Development of acute and chronic ovalbumin (OVA)-induced allergic asthma was assessed wee

217 to determine the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murin

218 nt susceptibility to pneumococcal infection, ovalbumin (OVA)-induced allergic lung inflammation (ALI)

219 Here we report that AQP3 potentiates ovalbumin (OVA)-induced murine asthma by mediating both

220 itro as well as in vivo in a murine model of ovalbumin (OVA)-induced systemic tolerance.

221 Naive and ovalbumin (OVA)-sensitized and challenged C57BL/6 wild-t

222 Basophils were purified from the lungs of ovalbumin (OVA)-sensitized and OVA-challenged (OVA-immun

223 Control and ovalbumin (OVA)-sensitized BALB/cJ mice were exposed via

224 Ovalbumin (OVA)-sensitized C57BL/6 mice were exposed to

225 Mice were then ovalbumin (OVA)-sensitized during the acute infection (3

226 Ovalbumin (OVA)-sensitized mice were desensitized to OVA

227 Ovalbumin (OVA)-specific, staphylococcal enterotoxin A (

228 srupted, were sensitized and gavage fed with ovalbumin (OVA).

229 in WT and FHL2-knock out (FHL2-KO) mice with ovalbumin (OVA).

230 and the major dietary protein and allergen, ovalbumin (OVA).

231 Il4raF709 mice were enterally sensitized to ovalbumin (OVA).

232 Mice were sensitized and challenged with ovalbumin (OVA).

233 B/c mice were sensitized and challenged with ovalbumin (OVA).

234 -) ) and wild-type mice were sensitized with ovalbumin (OVA).

235 of the muc5ac transcript in mice exposed to ovalbumin (OVA).

236 o-mid mass proteins (Trypsin Inhibitor (TI); Ovalbumin (OVA); Bovine Serum Albumin (BSA)), we observe

237 CAF09 and a surface-adsorbed model antigen [ovalbumin (OVA)] showed that a significantly larger frac

238 ntial allergenicity of food allergens, using ovalbumin (OVA, an egg white allergen) as a model allerg

239 ntracellular uptake of model cancer antigen (ovalbumin, OVA) by THP-1-differentiated macrophage-like

240 formation between heat-induced aggregates of ovalbumin (ovalbumin nanoparticles, OVAn) and linoleic a

241 hree proteins with high sequence similarity: ovalbumin, ovalbumin-related protein Y (OVAY), and ovalb

242 ntioxidant peptides, which were derived from ovalbumin, ovotransferrin and cystatin were isolated fro

243 We found that the ovalbumin phase-separates into core-shell particles with

244 O4@Al2O3 MNPs are functionalized with pigeon ovalbumin (POA), which contains Gal-alpha(1-->4)-Gal-bet

245 Subcutaneous immunization of mice with ovalbumin-polymer conjugates significantly enhanced anti

246 ctron tomography to measure the structure of ovalbumin precipitate particles salted out with ammonium

247 fic antibodies and enhanced proliferation of ovalbumin-reactive T cells associated with increased acc

248 min, ovalbumin-related protein Y (OVAY), and ovalbumin-related protein X (OVAX).

249 ns with high sequence similarity: ovalbumin, ovalbumin-related protein Y (OVAY), and ovalbumin-relate

250 Sensitization and challenge with ovalbumin reproduced hallmark features of asthma.

251 This study compares ovalbumin's allergenicity when it is aggregated as large

252 eosinophil peroxidase enhanced responses to ovalbumin seen after immunization.

253 nanostructures comprised of crystallites of ovalbumin self-assemble into a well-defined bicontinuous

254 ype (WT) and EP2(-/-) mice were subjected to ovalbumin sensitization and acute airway challenge.

255 ng IL-4 and IL-13 expression were induced by ovalbumin sensitization and challenge prior to acute lun

256 n response to Aspergillus fumigatus, but not ovalbumin sensitization and challenge, are activated by

257 The mouse asthma model was made by ovalbumin sensitization and challenge.

258 roncho-constrictions, even in the absence of ovalbumin sensitization and inflammation.

259 BALB/c mice without and with ovalbumin sensitization/challenge were infected with can

260 ecifically blocks cellular ADAM8 activity in ovalbumin-sensitized and challenged Balb/c mice.

261 ex vivo, were intratracheally injected into ovalbumin-sensitized and ovalbumin aerosol-challenged le

262 sed in the skin of cathelicidin knockout and ovalbumin-sensitized filaggrin mutant mice.

263 Treatment of ovalbumin-sensitized mice with pLR during allergen chall

264 ASMCs of asthmatic patients and in lungs of ovalbumin-sensitized mice.

265 ay smooth muscle from asthmatic patients and ovalbumin-sensitized mice.

266 on symptomatology and immune responses in an ovalbumin-sensitized mouse model of food allergy.

267 involved in asthmatic-like attacks using the ovalbumin-sensitized murine model of the disease, and id

268 Studies in mice using the model antigen Ovalbumin, showed that both combinations enhanced lymph

269 se, cholangitis developed in mice expressing ovalbumin simultaneously in biliary epithelia and entero

270 At low concentrations, ovalbumin-sized nanoparticles reach the primary filtrate

271 2 but significantly less IL-10 production by ovalbumin-specific CD4(+) T cells, resulting in prolifer

272 FN-gamma(+)) cells upon coculture with naive ovalbumin-specific CD4(+) T lymphocytes ex vivo.

273 H4R(-/-) mice had a reduced amount of ovalbumin-specific IgE, a reduced number of splenocytes

274 rausnitzii A2-165 stimulated BMDCs increased ovalbumin-specific T cell proliferation and reduced the

275 to ovalbumin, F. prausnitzii A2-165 enhanced ovalbumin-specific T cell proliferation and reduced the

276 s examined by assessment of proliferation of ovalbumin-specific T cells in rat insulin promoter-membr

277 bited the proliferation of lung-infiltrating ovalbumin-specific T cells.

278 CTLs derived from ovalbumin-specific T-cell receptor transgenic mice were

279 express SIINFEKL peptide, the ligand for the ovalbumin-specific TCR transgenic OT-I cells.

280 Adoptive transfer of ovalbumin-specific TH2 and TH9 cells was used to assess

281 by co-cultures of DCs from infected mice and ovalbumin-specific, MHC class II-restricted alpha/beta (

282 escued IgE production by minocycline-treated/ovalbumin-stimulated B cells.

283 This work illustrates the links between ovalbumin structure after heating and allergenicity pote

284 The influence of ovalbumin structure on Ig production upon sensitization

285 d tolerance induced by inhalation of soluble ovalbumin, suppressing the normal generation of forkhead

286 lly failed to cross-present male antigens or ovalbumin to CD8(+) T cells.

287 Conjugation of ovalbumin to the micelles significantly enhanced antigen

288 cells in rat insulin promoter-membrane-bound ovalbumin transgenic mice after sham or IRI procedures.

289 the present work, we determined that murine ovalbumin-transgenic (OT-1) CD8(+) T cells recognize the

290 as explored by stimulating OTI-Tc cells with ovalbumin-transgenic antigen-presenting cells in the pre

291 ia hepatic nuclear factor 4alpha and chicken ovalbumin upstream promoter transcription factor I/II.

292 n partially through up-regulation of chicken ovalbumin upstream promoter transcription factor II (COU

293 ale mouse embryos lacking Coup-tfII (chicken ovalbumin upstream promoter transcription factor II) in

294 m stem/progenitor cells that express chicken ovalbumin upstream promoter transcription factor II.

295 Transcription factor CTIP2 (chicken ovalbumin upstream promoter transcription factor-interac

296 Here, we have identified chicken ovalbumin upstream promoter-transcription factor II (COU

297 The nuclear receptor Chicken Ovalbumin Upstream Promoter-Transcription Factor II (COU

298 Chicken ovalbumin upstream promoter-transcription factor II (COU

299 reduction in murine response to experimental ovalbumin vaccination.

300 gens HDM and papain and a classical allergen ovalbumin was evaluated in vivo in mice deficient for TS

301 Ovalbumin was used as a model antigen.

302 nulation capacities of native and aggregated ovalbumin were measured with sera from egg-allergic chil

303 Surprisingly, systemic priming with ovalbumin, with or without adjuvants, circumvents the re